Pharvaris' Deucrictibant Shows Promise in HAE Prophylaxis and On-Demand Treatment — Pharvaris N.V.

Event summary

Pharvaris published Phase 2 study results for deucrictibant in The Lancet Haematology, showing efficacy in both prophylactic and on-demand treatment of HAE attacks.
CHAPTER-1 study demonstrated statistically significant reduction in HAE attack occurrence and improved quality of life.
RAPIDe-1 study showed significant reduction in attack severity and faster symptom relief with deucrictibant immediate-release capsules.
Topline data from Phase 3 studies CHAPTER-3 and RAPIDe-3 anticipated in Q3 2026 and already presented at AAAAI 2026 Annual Meeting, respectively.

The big picture

Pharvaris' deucrictibant represents a novel approach to managing bradykinin-mediated angioedema, potentially offering an oral alternative to injectable therapies. The dual formulation strategy could address both prophylactic and acute treatment needs, aligning with broader industry trends toward patient-friendly drug delivery methods. Success hinges on regulatory approval and differentiation in a competitive HAE treatment landscape.

What we're watching

Regulatory Pathway: Whether Pharvaris can secure regulatory approval for deucrictibant based on the Phase 3 data, particularly given the orphan drug designation status.
Market Differentiation: How deucrictibant's dual formulation strategy (immediate-release and extended-release) will position it against existing HAE treatments.
Clinical Validation: The pace at which additional Phase 3 data from CHAPTER-3 and CREAATE studies will solidify deucrictibant's role in both HAE and AAE-C1INH treatment.